DLS mGluR1/5 signaling activation in instrumental conditioning and differential behavioral sensitivity to A–O changes with training duration. by Vincent Paget-Blanc (21807763)

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial by Daniëlle B. P. Eekers (5560430)

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

Whole brain FC matrix (comprising of 100 ROI) based on the coherence. by Ishita Rai Bansal (13162713)

Changes in mortality and DALYs per100,000 rates by cancer types from 1990 to 2019 in Iran; a) Mortality rate; b) DALYs per100000 rate. by Mitra Darbandi (17967619)

This is the raw data of IHC-2 、qPCR、Masson and HE in Rat、qPCR in human peritoneal solution and qPCR in Met-5A cell. by Yangyang Yin (14323701)

Subjects:

Comparison of the MMP in HL-1 cells exposed to LG, NG, HG and IHG between short- (12h) and long-time (72h) glucose treatment. by Patrick Mordel (17020879)

Overall survival of patient with de novo AML in South Korea, from 2011 to 2020 by diagnosis period: (a) age≥ 65 and (b) age <65. by Hyun Jin Han (18592254)

Baseline clinical profile of hospitalized COVID-19 patients with low and high renalase. by Basmah Safdar (12213257)

Cox hazard regression model of renalase and primary composite outcome. by Basmah Safdar (12213257)

Flow chart of study patients from all COVID-19 admissions to the institution from March to July 2020. by Basmah Safdar (12213257)

Time adjusted survival curves for high vs. low renalase among patients with COVID-19 disease (using first quartile as cutoff). by Basmah Safdar (12213257)

Time-adjusted survival curve for IL-6 and renalase among patients with COVID-19 disease (A) For composite outcome^a: High renalase + High IL-6; High renalase + Low IL-6;... by Basmah Safdar (12213257)

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

“…Following a 20-day treatment with 2 M NH₄OAc (pH 7), the number of peptides identified using the LP(HPMA)-coated capillary decreased by 18.1% compared to the untreated LP(HPMA)-coated capillary; in contrast, the peptide numbers for the LPA-coated capillary decreased by 26.7% relative to its untreated counterpart. …”

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

“…Following a 20-day treatment with 2 M NH₄OAc (pH 7), the number of peptides identified using the LP(HPMA)-coated capillary decreased by 18.1% compared to the untreated LP(HPMA)-coated capillary; in contrast, the peptide numbers for the LPA-coated capillary decreased by 26.7% relative to its untreated counterpart. …”

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

“…Following a 20-day treatment with 2 M NH₄OAc (pH 7), the number of peptides identified using the LP(HPMA)-coated capillary decreased by 18.1% compared to the untreated LP(HPMA)-coated capillary; in contrast, the peptide numbers for the LPA-coated capillary decreased by 26.7% relative to its untreated counterpart. …”

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

“…Following a 20-day treatment with 2 M NH₄OAc (pH 7), the number of peptides identified using the LP(HPMA)-coated capillary decreased by 18.1% compared to the untreated LP(HPMA)-coated capillary; in contrast, the peptide numbers for the LPA-coated capillary decreased by 26.7% relative to its untreated counterpart. …”

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

“…Following a 20-day treatment with 2 M NH₄OAc (pH 7), the number of peptides identified using the LP(HPMA)-coated capillary decreased by 18.1% compared to the untreated LP(HPMA)-coated capillary; in contrast, the peptide numbers for the LPA-coated capillary decreased by 26.7% relative to its untreated counterpart. …”

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

“…Following a 20-day treatment with 2 M NH₄OAc (pH 7), the number of peptides identified using the LP(HPMA)-coated capillary decreased by 18.1% compared to the untreated LP(HPMA)-coated capillary; in contrast, the peptide numbers for the LPA-coated capillary decreased by 26.7% relative to its untreated counterpart. …”

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

“…Following a 20-day treatment with 2 M NH₄OAc (pH 7), the number of peptides identified using the LP(HPMA)-coated capillary decreased by 18.1% compared to the untreated LP(HPMA)-coated capillary; in contrast, the peptide numbers for the LPA-coated capillary decreased by 26.7% relative to its untreated counterpart. …”